Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor blockers (ARBs) are already known to have an anti-inflammatory effect, to decrease kidney damage in ADPKD [43] and lower KYNA synthesis in the kidney [23, 24]. The gene discussed is AGTR1; the disease is autosomal dominant polycystic kidney disease.